Loading
The one trial still testing an antibody-drug conjugate in mesothelioma, combining it with PD-1 blockade on the theory that payload-induced cell death primes an immune response.
This National Cancer Institute study enrolled 49 patients with mesothelin-positive pleural mesothelioma after prior therapy. A phase 1 run-in established the dose of anetumab ravtansine with pembrolizumab, and the phase 2 part randomised patients to pembrolizumab with or without the conjugate. The study is active but no longer recruiting, with results awaited. It is the only remaining clinical test of an ADC in mesothelioma recorded on ClinicalTrials.gov.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
49 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2024-10-16), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2024-10-16), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2024-10-16), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumabprimary | Phase 1 Cohort: Anetumab Ravtansine & MK-3475 | 13 | 6.5 mg/kg iv | - | - | link |
| Phase 2 Overall Survival | Group I (Pembrolizumab) | 17 | 0 participants | - | - | link |
| Group II (Anetumab Ravtansine, Pembrolizumab) | 18 | 2 participants | ||||
| Phase 2 Progression Free Survival | Group I (Pembrolizumab) | 17 | 10 participants | 1.81 (0.73 to 4.51) | 0.1952 | link |
| Group II (Anetumab Ravtansine, Pembrolizumab) | 18 | 9 participants |
Shares Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Anetumab ravtansine, Mesothelin, Mesothelioma and the tag owner-request.
Shares Mesothelioma and the tag owner-request.
Shares Immune checkpoint inhibitors and the tag owner-request.
Shares National Cancer Institute (NIH) and the tag owner-request.
Shares National Cancer Institute (NIH) and the tag owner-request.
Shares Mesothelin, Mesothelioma, National Cancer Institute (NIH).
Shares Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work, Anetumab ravtansine.
Shares Mesothelioma, Pembrolizumab, Immune checkpoint inhibitors.